ArticleVirologica Sinica2026
A semi-replicating VSV (srVSV)-based platform for developing broad-spectrum mucosal vaccines against influenza A viruses.
Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A viruses (IAVs) are significant respiratory pathogens characterized by high mutation rates and frequent genetic reassortments, underscoring the need for vaccines that can induce robust and broadly protective mucosal immunity. While replication-competent vesicular stomatitis virus (VSV) vectors have the potential to elicit mucosal immunity, their neurovirulence raises significant safety concerns. Herein, we report that a semi-replicating VSV (srVSV) vector, composed of one VSV with the glycoprotein (G) gene deleted (rVSVΔG) and another with the L gene deleted (rVSVΔL), has improved safety. Using srVSV, we constructed a monovalent vaccine (srVSV-N1), expressing the neuraminidase 1 (N1) of IAV. A single intranasal dose of srVSV-N1 elicited both systemic and mucosal immune responses against N1, and provided sterilizing immunity against homologous influenza virus. We further generated a bivalent IAV vaccine (srVSV-N1/N2), co-expressing N1 and N2. A single intranasal dose of srVSV-N1/N2 conferred 80% protection against heterologous IAVs (H1N1 and H3N2). Notably, low-dose priming immunization followed by a high-dose boost with srVSV-N1/N2 fully protected mice against lethal heterologous IAV challenges. These findings demonstrate the potential of the srVSV platform for developing mucosal vaccines against IAVs and other respiratory viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.